Propranolol or Hydrochlorothiazide Alone for the Initial Treatment of Hypertension: IV. Effect on Plasma Glucose and Glucose Tolerance

To evaluate the short-term and long-term effectiveness of propranolol and hydrochlorothiazide monotherapy For hypertension, 683 hypertensive men were randomized to treatment with either propranolol or hydrochlorothiazide. Both drugs increased the average fasting plasma glucose level by approximately...

Full description

Saved in:
Bibliographic Details
Published inHypertension (Dallas, Tex. 1979) Vol. 7; no. 6, Part 1; pp. 1008 - 1016
Main Authors RAMIREZ, E. A, TALMERS, F. N
Format Journal Article
LanguageEnglish
Published Philadelphia, PA American Heart Association, Inc 01.11.1985
Hagerstown, MD Lippincott
Subjects
Antihypertensive agents
Biological and medical sciences
Cardiovascular system
Medical sciences
Pharmacology. Drug treatments
Diuretic
Human
Hypertension
Chemotherapy
Hyperglycemia
Cardiovascular disease
Thiazide
Comparative study
Beta blocking agent
Online AccessGet full text

Cover

More Information
Summary:To evaluate the short-term and long-term effectiveness of propranolol and hydrochlorothiazide monotherapy For hypertension, 683 hypertensive men were randomized to treatment with either propranolol or hydrochlorothiazide. Both drugs increased the average fasting plasma glucose level by approximately 5 mg/dl after 10 weeks (p < 0.001) and 1 year (p < 0.001) of treatment, but the elevation persisted only in the propranolol-treated group 1 month after discontinuing the yearlong treatment (p < 0.01). A subset of 191 patients had 2-hour glucose tolerance tests. Hydrochlorothiazide increased the average 2-hour oral glucose tolerance test result by 18.0 mg/dl after 10 weeks (p < 0.001), an increase significantly higher than that induced by propranolol (p < 0.012). After 1 year of treatment, however, propranolol also increased the average 2-hour oral glucose tolerance test result (p < 0.05) and there was no significant difference between drugs. The hyperglycemic effects were dose-related, which suggests that both drugs should be administered at their lowest effective dosage. The clinical importance of the persistent fasting plasma glucose elevation in propranololtreated patients 1 month after discontinuing treatment is unknown.
ISSN:0194-911X
1524-4563